Xeomin, una neurotoxina botulínica tipo A libre de proteínas complejantes

Terradas, S.
October 2012
El Farmacéutico Hospitales;oct2012, Issue 199, p18
Academic Journal
Xeomin® is a pharmaceutical presentation of highly purified botulinum neurotoxin type A. The absence of complexing proteins in this formulation apparently does not affect its physicochemical stability, nor the risk of spread outside the target muscles nor the postinjection response time. Furthermore, appears to be less immunogenic due to its lower protein load. Xeomin® has proven to be safe and effective in the treatment of cervical dystonia, of benign essential blepharospasm and of post-stroke upper limb spasticity, having shown non inferiority in the clinical trials versus Botox®, performed in the two first indications.


Related Articles

  • Ask Dr Andrew.  // Woman's Day (Australia Edition);2/13/2006, Vol. 58 Issue 7, p64 

    The article presents information on Botox. Botulinum toxin is a neurotoxin initially used to treat strabismus, blepharospasm and cervical dystonia. Currently, it is used cosmetically, particularly to improve and relax frown lines. Risks associated with the procedure include headache, dry eyes...

  • Langzeittherapie fokaler Dystonien und des Hemispasmus facialis mit Botulinum-Toxin A. Vogt, T.; Lüssi, F.; Paul, A.; Urban, P. // Der Nervenarzt;Aug2008, Vol. 79 Issue 8, p912 

    Background: Although botulinum neurotoxin A has been used for many years to treat focal dystonia-like blepharospasm (BLSP), cervical dystonia (CD), and hemifacial spasm (HFS) as vascular compression disorder of the facial nerve, there are few data on its long-term efficacy. Methods: We analysed...

  • Fifteen-Year Experience in Treating Blepharospasm with Botox or Dysport: Same Toxin, Two Drugs. Bentivoglio, A. R.; Fasano, A.; Ialongo, T.; Soleti, F.; Fermo, S. Lo; Albanese, A. // Neurotoxicity Research;2009, Vol. 15 Issue 3, p224 

    Objectives To compare the clinical characteristics and the long-term outcome of a large series of patients with blepharospasm (BS) treated with the two most used brands of BoNT-A over the last 15 years. Methods We have reviewed the clinical charts of 128 patients with BS who received botulinum...

  • blepharospasm. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p106 

    An encyclopedia entry for the term "blepharospasm" is presented. It involves the prolonged, involuntary contraction of one of the muscles controlling the eyelids, causing them to close. Cited factors causing this condition include photophobia, damage to the cornea, and dystonia, for which...

  • Clinical Profile of Botulinum Toxin A in Patients with Chronic Headaches and Cervical Dystonia: A Prospective, Open-Label, Longitudinal Study Conducted in a Naturalistic Clinical Practice Setting. Dowson, Andrew J; Kilminster, Shaun G; Salt, Rebecca // Drugs in R&D;2008, Vol. 9 Issue 3, p147 

    BACKGROUND AND OBJECTIVES: Some evidence for the efficacy of botulinum toxin A as a preventive treatment for chronic primary headaches has been reported in randomized, controlled clinical studies. This study investigated the clinical profile of botulinum toxin A in a naturalistic clinical...

  • Mehanizam djelovanja i terapija botulinum toksinom. Alajbegović, Azra; Alajbegović, Salem; HalimaResić // Medicinski Arhiv;2008, Vol. 62 Issue 1, p53 

    Botulinum neurotoxin (BoNT) is produced by Clostridium botulinum as a complex of proteins containing the neurotoxin itself and other nontoxic proteins. Activation of the neurotoxin occurs upon proteolytic cleavage into the heavy and light chains. This di-chain moiety is essential for neurotoxin...

  • Neuroleptic-Induced Tardive Cervical Dystonia: Clinical Series of 20 Patients. Godeiro-Junior, Clecio; Felício, Andre C.; de Carvalho Aguiar, Patrícia; Borges, Vanderci; Silva, Sonia M. A.; Ferraz, Henrique B. // Canadian Journal of Neurological Sciences;Mar2009, Vol. 36 Issue 2, p222 

    Background: Cervical dystonia (CD) may be classified according to the underlying cause into primary or secondary CD. Previous exposure to neuroleptics is one of the main causes of adult-onset secondary dystonia. There are few reports that characterize the clinical features of primary CD and...

  • Causes for Treatment Delays in Dystonia and Hemifacial Spasm: A Canadian Survey. Jog, Mandar; Chouinard, Sylvain; Hobson, Doug; Grimes, David; Chen, Robert; Bhogal, Meetu; Simonyi, Susan // Canadian Journal of Neurological Sciences;Sep2011, Vol. 38 Issue 5, p704 

    Background: Dystonia must be accurately diagnosed so that treatment can be administered promptly. However, dystonia is a complex disorder, with variable presentation, which can delay diagnosis. Methods: Data were gathered by questionnaire from 866 patients with dystonia or hemifacial spasm (HFS)...

  • Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. Burbaud, Pierre; Ducerf, Camille; Cugy, Emmanuelle; Dubos, Jean-Louis; Muller, François; Guehl, Dominique; Dehail, Patrick; Cugy, Didier; Moore, Nicholas; Lagueny, Alain; Joseph, Pierre-Alain // Journal of Neurology;Sep2011, Vol. 258 Issue 9, p1670 

    Botulinum toxin (BTA) is a safe and effective therapeutic tool for many neurological conditions but few studies have investigated its real cost in neurological practice. We evaluated the daily cost of botulinum toxin type A (BTA) treatment through a cost effectiveness analysis alongside a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics